Tirzepatide 30mgResearch Peptide · PepC.Labs

Overview

Tirzepatide is a dual GIP and GLP-1 receptor agonist research peptide. It sits in the same broader research category as Retatrutide, though with a narrower receptor activation profile. Published Phase 2 and Phase 3 clinical trial data has reported observations on metabolic markers in peer-reviewed journals.

This vial contains 30mg of Tirzepatide as a lyophilised powder for reconstitution with sterile diluent in the laboratory. The 30mg vial is double the size of the standard 15mg presentation and is suited to research protocols that benefit from a larger working stock at the same 10mg/mL concentration.

What is Tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously engages two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual agonist design distinguishes it from single-agonist GLP-1 analogues such as semaglutide and liraglutide.

Published research has investigated Tirzepatide in the context of:

Background on Incretin Research

The incretin system comprises hormones released from the gut in response to nutrient intake that modulate insulin secretion from pancreatic beta cells. GLP-1 and GIP are the two major endogenous incretin hormones. Earlier research compounds in this lineage targeted only the GLP-1 receptor; Tirzepatide extends this by adding GIP receptor activation to the profile.

Researchers have investigated whether dual activation of GIP and GLP-1 receptors produces effects that differ from single-agonist research compounds, particularly in the context of preclinical models of metabolic dysfunction.

Published Research

Preclinical research on Tirzepatide has been conducted in rodent and non-human primate models. Published clinical trial data from Phase 2 and Phase 3 research studies has appeared in peer-reviewed journals. Areas of published investigation include:

Tirzepatide is supplied strictly as a research reagent for laboratory research purposes.

Quality and Verification

Every batch ships with a batch-specific Certificate of Analysis documenting purity by HPLC (≥99%) and mass spectrometry confirmation of peptide identity. The vial is shipped lyophilised to preserve stability during transit and should be stored at -20°C prior to reconstitution and 2-8°C after reconstitution in the laboratory.

Further Reading

For background on handling lyophilised research peptides, see our reconstitution calculator. See also our long-form description of Retatrutide for context on the broader triple agonist research category.

Disclaimer

For research use only. Not for human consumption. The information provided is for educational and research purposes only. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult published peer-reviewed literature before designing research protocols.